Preventing Recurrence and Improving Outcomes for Your Patients Following Resection of Stage IIB/C Melanoma: The Role of Adjuvant Immunotherapy

Questions marked with a * are required
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
All of the following biomarkers are associated with risk of melanoma recurrence except:
Adjuvant treatment with either nivolumab or pembrolizumab are both effective in improving recurrence-free survival in patients with resected stage IIB/C melanoma.
Which of the following treatments are ideal for managing Grade 3 irAEs in early-stage melanoma patients receiving immunotherapy?
A 45-year-old tennis player presented to the clinic concerned about a few moles on her arms. She had noticed that one of the moles was growing in size. She comes with a history of mild hypothyroidism. Biopsy results confirm a 3.2 mm melanoma with ulceration, wild-type BRAF, and a mitotic rate of 12 mits/HPF. The dermatologist determines surgery, and the patient is very clear she would like to reduce her risk of recurrence as much as possible. What treatment option would you recommend?
A 60-year-old patient who has been on pembrolizumab for six months for Stage III melanoma develops severe abdominal pain and diarrhea that requires taking time off from work. What would be the best next step?
What is your job role?
What is your type of practice?
How many years have you been in practice?
Please estimate the number of patients with melanoma that you treat each month:
How many years have you been using immunotherapy treatments in the clinic?
Were the following learning objectives met?
Strongly Agree
Strongly Disagree
Interpret data from studies evaluating the use of adjuvant immunotherapy following resection of stage IIB/C melanoma
Facilitate the inclusion of adjuvant immunotherapy following resection of stage IIB/C melanoma as part of individualized patient management plans
Prepare strategies for detecting and mitigating the irAEs associated with immunotherapies used for the treatment of patients with early-stage melanoma
Support multidisciplinary team approaches to the management of patients with early-stage melanoma
Please rate your confidence in your ability to manage patients with stage IIB/C melanoma  on a scale of 1 to 5, where 1 means "not confident at all" and 5 means "very confident."
As a result of this course, I will likely make changes to my practice.
If YES, in which of the following categories? (Please check all that apply)
In particular, as a result of this course, I will be more likely to implement the following changes:
(Please check all that apply)
What barriers may prevent/inhibit changes in practice recommended in this activity?
 (Please check all that apply.):
Please evaluate this activity as a whole.
Strongly agree
Strongly disagree
The learning format was interactive and engaging
The content was pertinent to my professional needs
The activity will ultimately benefit patient care
I would recommend this activity to colleagues
Do you feel a commercial product, device, or service was inappropriately promoted in this educational activity? 
If YES, please comment:
What was the most effective aspect(s) of this learning activity? (Please check all that apply.):
Do you have suggestions for improving the session or for topics for future activities?
 (Please check all that apply.):
Please evaluate the faculty: Jason J. Luke, MD
Med Learning Group has my permission to fax or email information to me about further programs.
At times, MLG partners to conduct educational outcomes analyses on treatment and/or diagnosis behavior that are all deidentified and rolled-up across all learners.
Any additional comments are welcome below. 
Powered by QuestionPro